Cytokinetics CEO defends Royalty Pharma deal: 'That narrative was hijacked'
临床3期
Cytokinetics CEO Robert Blum blamed investor frustration over a deal with Royalty Pharma on a “hijacked” narrative that the company would be better off selling itself than continuing on its own.
On Wednesday, Cytokinetics announced an up to $575 million
deal
with Royalty Pharma and a $500 million
public offering
to fund the potential launch of aficamten for a rare heart disease and to run another Phase 3 study for omecamtiv mecarbil, which was rejected by the FDA last year. The news sent Cytokinetics shares
$CYTK
down 17% on Thursday morning amid investor frustration that a rumored deal for the company might never happen.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。